Single Cell Analysis Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global single cell analysis market growth forecasted to transform from USD 3.7 billion in 2024 to USD 6.9 billion by 2029, driven by a CAGR of 13.6%. Growth of the single-cell analysis market can be attributed to factors such as the rising incidences of cancer and immunological disorders, technological developments in single-cell analysis products, growing focus on advancement of stem cell research, and increasing focus on advancement of biotechnology sector. Additionally, growing research activities for the development of personalized medicine is driving the growth of single-cell analysis market. Also, increasing research and development investments and fundings in pharmaceutical and biotechnology industries for the management of complex diseases is anticipated to promote the single-cell analysis market growth. Moreover, increasing adoption of single-cell sequencing to study cellular heterogeneity is likely to support the growth of the market in coming years. However, high cost of single-cell analysis products may hamper the growth of the market.

Single Cell Analysis Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the Single Cell Analysis Market

Single Cell Analysis Market Dynamics

DRIVER: Technological advancements in single-cell analysis products

Players operating in the single-cell analysis market increasingly focus on developing more economical, technologically advanced, and easy-to-use instruments. For instance, in February 2024, 10X Genomics launched the GEM-X technology, next generation of its single-cell technology architecture that will power new assays of its Chromium platform. Chromium GEM-X Single Cell Gene Expression v4 and GEM-X Single Cell Immune Profiling v3 assays are the first two products to use 10X Genomics’s new GEM-X technology architecture. Similarly, in April 2023, Standard BioTools launched a new imaging technology, the Hyperion XTi Imaging System, during the American Association for Cancer Research (AACR) meeting in Orlando.

RESTRAINT: High cost of single-cell analysis products

Cell biology involves extensive research on the development of new therapies, such as stem cell and gene therapies. The instruments, reagents, and other products associated with these research activities are required to be of high quality to obtain accurate results. The use of advanced single-cell analysis techniques is largely dependent on the cost of instruments. Flow cytometers, microfluidic devices, and high-content screening systems equipped with advanced features and functionalities are generally priced at a premium. Advancements in various instruments have led to higher prices than previous-generation instruments due to their expensive development process. For instance, the price of ATTUNE NxT Flow Cytometer Invitrogen offered by Thermo Fisher Scientific Inc. is USD 30,000 each. Similarly, the price of SMARTer ICELL8 cx Single-Cell System offered by Takara Bio Inc. is USD 17,995 each.

OPPORTUNITY: High growth potential of single-cell sequencing

Single-cell sequencing (SCS) helps researchers to understand cellular heterogeneity and transcriptional randomness. Advancements in single-cell sequencing helps to improve detection and analysis of infectious disease outbreaks, antibiotic drug-resistant strains, and microbial diversities in the environment. As single-cell sequencing technology provides detailed information about genetic mutations, companies are focusing on development of instruments and reagents that are suitable for single-cell sequencers. For instance, Illumina, Inc. (US), one of the major players in the single-cell analysis market, offers integrated ultra-low-input and single-cell RNA sequencing workflows (with the SMARTer Ultra Low Input RNA Kit by US-based Clontech Laboratories Inc., combined with the Nextera XT DNA Library Preparation Kit and Illumina sequencing technology) that help in the simplification of the entire process, from library preparation to data analysis and biological interpretation. Considering the high-growth potential of this segment, several advanced SCS instruments are expected to be developed and launched in the market in the coming years.

CHALLENGE: Technical challenges associated with single cell analysis

Despite varied applications and advantages of single-cell analysis, it may sometimes show irregular results as a result of technical limitations associated with the single-cell analysis technique. Some of the technical limitations associated with single-cell analysis include technological biases and amplification errors. Technological biases such as amplification biases and batch effects can affect the results of single-cell analysis. Amplification steps in single-cell analysis may introduce biases, leading to the uneven representation of transcripts and potential distortion of gene expression profiles. Also, Variability between different experimental batches can impact the reproducibility and comparability of single-cell datasets. Therefore, technical challenges associated with single cell analysis are expected to affect the growth of the single-cell analysis market.

Global Single Cell Analysis Market Ecosystem Analysis

The single-cell analysis market ecosystem comprises raw material suppliers, single-cell analysis product manufacturers, and end users such as academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers. Single-cell analysis products manufacturers provide consumables and instruments.

The human cells segment dominated the single cell analysis industry in 2023.

Based on cell type, the single cell analysis market is segmented into human cells, animal cells, and microbial cells. In 2023, the human cells segment dominated the market owing to growing applications of human stem cells for development of cell-based therapies. Human stem cells are witnessing a significant demand due to the increasing investments in cancer research globally which is expected to support the segment growth. Additionally, human cells are widely used for the diagnosis and treatment of diseases as well as for studying the anatomy and cell functions thus, increasing research activities for cell analysis is anticipated to propel the segment growth in the market. Moreover, growth in stem cell research is likely to propel the segment growth.

The flow cytometry segment dominated the single cell analysis industry in 2023.

Based on the technique, the single-cell analysis market is segmented into flow cytometry, next-generation sequencing, polymerase chain reaction, microscopy, mass spectrometry, and other techniques. In 2023, the flow cytometry segment held the largest market share in the global market owing to growing focus on development of cellular therapies due to increasing rate of cancer and innovations in flow cytometry techniques. Flow cytometry rapidly measures specific characteristics of a large number of individual cells that assist researchers in understanding cell morphologies extensively thus, the utilization of flow cytometry for single-cell analysis to obtain precise results is expected to support the segment growth. Moreover, growing adoption of advanced technologies such as flow cytometry for cell analysis is likely to boost the segment growth.

North America dominated the single cell analysis industry in 2023.

To know about the assumptions considered for the study, download the pdf brochure

The global single cell analysis market is segmented into six major regions—North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa. North America accounted for the largest share of single-cell analysis market in 2023, followed by Europe and the Asia Pacific. Factors such as increasing development and manufacturing of cell-based therapies, significant investments in R&D activities, and presence of a well-established healthcare sector are responsible for the largest share of North America region in single-cell analysis market.

Key players in the single-cell analysis market include Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), BD (US), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), 10x Genomics (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), DiaSorin S.p.A. (Italy), Standard BioTools (US), Tecan Trading AG (Switzerland), Sartorius AG (Germany), Corning Incorporated (US), Cytek Biosciences (US), Takara Bio Inc. (Japan), BIOMÉRIEUX (France), Revvity (US), Bio-Techne (US), PacBio (US), Bruker (US), Promega Corporation (US), Oxford Nanopore Technologies plc. (UK), The Menarini Group (Italy), Singleron Biotechnologies (Germany), BICO (Sweden), Fluent BioSciences (US), RareCyte, Inc. (US), Cell Microsystems (US), NanoCellect Biomedical (US), Sphere Fluidics (UK), On-chip Biotechnologies Co., Ltd. Corporation (Japan), and Apogee Flow Systems Ltd. (UK).

Scope of the Single Cell Analysis Industry:

This report categorizes the single-cell analysis market into the following segments

By Product

• Consumables
• Beads
• Microplates
• Reagents
• Assay Kits
• Immuno Assays
• Cell-based Assays
• Other Consumables
• Instruments
• Flow Cytometers
• NGS Systems
• PCR Instruments
• Spectrophotometers
• Cell Counters
• Microscopes
• HCS Systems
• Microarrays
• Other Instruments

By Cell Type

• Human Cells
• Animal Cells
• Microbial Cells

By Technique

• Flow cytometry
• Next-generation sequencing (NGS)
• Polymerase chain reaction (PCR)
• Microscopy
• Mass spectrometry
• Other techniques

By Application

• Research Applications
• Cancer Research
• Immunology Research
• Neurology Research
• Stem Cell Research
• Other Research Applications
• Medical Applications
• Non Invasive Prenatal Diagnosis
• In Vitro Fertilization
• Circulating Tumor Cell Detection

By End User

• Academic & Research Laboratories
• Biotechnology & Pharmaceutical Companies
• Hospitals & Diagnostic Laboratories
• Cell Banks & IVF Centers

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East
  • GCC Countries
  • Saudi Arabia (KSA)
  • United Arab Emirates (UAE)
  • Rest of GCC Countries (RoGCC)
  • Rest of Middle East (RoME)
• Africa

Recent Developments of Single Cell Analysis Industry:

• In June 2024, Illumina, Inc. launched its latest chemistry, XLEAP-SBS for its NextSeq 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments. XLEAP-SBS chemistry is a faster, higher quality, and more robust sequencing-by-synthesis chemistry that delivers approximately 20% faster turnaround times.
• In October 2023, Danaher Corporation (Beckman Coulter Life Sciences) partnered with 10x Genomics to expand automation solutions for single cell assay workflows.
• In February 2023, BD launched BD Rhapsody HT Xpress System, a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity, potentially accelerating time to discovery across a wide range of disciplines, including immunology, genetic disease research, and cancer and chronic disease research..
• In February 2023, Ultima Genomics, Inc. and 10x Genomics collaborated to integrate 10x Genomics Chromium Single Cell Gene Expression solutions with Ultima’s advanced ultra-high throughput sequencing systems.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst